Monoamines and their Derivatives on GPCRs: Potential Therapy for Alzheimer’s Disease

(E-pub Ahead of Print)

Author(s): Eunice D. Farfán-García, Ricardo Gómez-Marques, Mónica Barrón-González, Teresa Pérez-Capistran, Martha C. Rosales-Hernández, Rodolfo Pinto-Almazán, Marvin A. Soriano-Ursúa*.

Journal Name: Current Alzheimer Research

Submit Manuscript
Submit Proposal


Albeit cholinergic depletion remains the key event in Alzheimer’s Disease (AD), recent information describes stronger links between monoamines (trace amines, catecholamines, histamine, serotonin, and melatonin) and AD than those known in the past century. Therefore, new drug design strategies focus efforts to translate the scope on these topics and to offer new drugs which can be applied as therapeutic tools in AD. In the present work, we reviewed the state-of-art regarding genetic, neuropathology and neurochemistry of AD involving monoamine systems. Then, we compiled the effects of monoamines found in the brain of mammals as well as the reported effects of their derivatives and some structure-activity relationships. Recent derivatives have triggered exciting effects and pharmacokinetic properties in both murine models and humans. In some cases, the mechanism of action is clear, essentially through the interaction on G-protein-coupled receptors as revised in this manuscript. Additional mechanisms are inhibition of enzymes for their biotransformation, regulation of free-radicals in the central nervous system and others for the effects on Tau phosphorylation or amyloid-beta accumulation. All these data make the monoamines and their derivatives attractive potential elements for AD therapy.

Keywords: Monoamines, monoaminergic neuropathology, drug design, GPCR, Tau-protein, Amyloid beta

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1570159X17666190409144558
Price: $95

Article Metrics

PDF: 1